Alvogen snags NRx's bipolar depression drug in $330M deal ahead of late-phase data drop

Alvogen has secured a low-risk shot at the treatment-resistant suicidal bipolar depression market. The deal gives the drugmaker the U.S. license to NRx Pharmaceuticals’ NRX-101—and it will only make the initial $10 million cash payment upon seeing positive data from a phase 2b/3 clinical trial of the candidate.